Xerostomia Therapeutics Global Market Top Companies, Trends and Future Prospects Details for Business Development 2033 | Bayer AG, 3M Company, Cipla Ltd., Lupin Limited, Synedgen Inc.

"The new report published by The Business Research Company, titled Xerostomia Therapeutics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the xerostomia therapeutics market size has grown strongly in recent years. It will grow from $2.04 billion in 2023 to $2.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The xerostomia therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

Chemotherapy's Role In Driving The Growth Of Xerostomia Therapeutics Market
The increasing adoption of chemotherapy in cancer treatment is expected to propel the growth of xerostomia therapeutics market going forward. Chemotherapy in cancer treatment refers to the use of powerful medications which is to kill or slow the growth of cancer cells. The rising acceptance of chemotherapy in cancer treatment is mainly due to its effectiveness in specifically targeting and eradicating cancerous cells throughout the body. Xerostomia therapeutics include saliva-stimulating medications or mouth rinses that improve saliva production and enhance taste perception, making it easier for patients to eat and maintain adequate nutrition. For instance, in the January 2022, according to the National Cancer Institute, a US based government agency, estimated that there are 18.1 million cancer survivors in the United States which amounts to 5.4% of the total population. By 2032, there will be 22.5 million cancer survivors worldwide, a 24.4% increase from the current estimate. Therefore, the increasing adoption of chemotherapy in cancer treatment is driving the growth of the xerostomia therapeutics market.

Advancements In Xerostomia Therapeutics
Major companies operating in the xerostomia therapeutics market are developing saliva substitutes to mimic the natural composition of saliva, providing relief to those suffering from xerostomia. Saliva substitutes effectively alleviate the discomfort of xerostomia by providing moisture, lubrication, pH balance, cleansing, and potentially other beneficial properties to the oral cavity, thereby improving oral health and quality of life. For instance, in September 2021, ICPA Health Products, an India based pharmaceutical company, launched Wet Mouth, a saliva substitute for treating individuals suffering from xerostomia. Wet Mouth is formulated with a mouth moisturizing technology that soothes and lubricates, providing relief from dry mouth symptoms for up to four hours. It helps to maintain a balanced pH in the mouth and is alcohol-free and sugar-free, serving as a breath freshener and moisturizing mouthwash with a refreshing peppermint flavor.

The xerostomia therapeutics market covered in this report is segmented -
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric

Buy Now & Get Exclusive Discount on this Report, Checkout link @ https://www.thebusinessresearchcompany.com/Discount?id=15700&type=discount

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd. , Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc

Contents of the report:
1. Executive Summary
2. Xerostomia Therapeutics Market Report Structure
3. Xerostomia Therapeutics Market Trends And Strategies
4. Xerostomia Therapeutics Market - Macro Economic Scenario
5. Xerostomia Therapeutics Market Size And Growth
…..
27. Xerostomia Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.